[{"address1": "1201 Orange Street", "address2": "Suite 600", "city": "Wilmington", "state": "DE", "zip": "19801", "country": "United States", "phone": "484 254 6134", "website": "https://www.nrxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan C. Javitt M.D., M.P.H.", "age": 67, "title": "Co-Founder, Chief Scientist Officer, Chairman & Interim CEO", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 825000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew Patrick Duffy", "age": 61, "title": "Chief Business Officer & Co-CEO of Hope Therapeutics", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 338000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael S. Abrams", "age": 54, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Riccardo  Panicucci Ph.D.", "age": 63, "title": "Chief Manufacturing & Technology Officer", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 240000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Suzanne  Messere", "title": "Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Philip T. Lavin Ph.D.", "age": 77, "title": "Chief Methodologist", "yearBorn": 1947, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.18, "open": 2.2, "dayLow": 2.2, "dayHigh": 2.41, "regularMarketPreviousClose": 2.18, "regularMarketOpen": 2.2, "regularMarketDayLow": 2.2, "regularMarketDayHigh": 2.41, "payoutRatio": 0.0, "beta": 1.917, "forwardPE": 9.48, "volume": 544239, "regularMarketVolume": 544239, "averageVolume": 472340, "averageVolume10days": 602340, "averageDailyVolume10Day": 602340, "bid": 1.73, "ask": 2.7, "bidSize": 2, "askSize": 2, "marketCap": 70164200, "fiftyTwoWeekLow": 1.4, "fiftyTwoWeekHigh": 6.01, "allTimeHigh": 769.9, "allTimeLow": 1.1, "priceToSalesTrailing12Months": 289.93472, "fiftyDayAverage": 2.5988, "twoHundredDayAverage": 2.642095, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 69663376, "profitMargins": 0.0, "floatShares": 20326385, "sharesOutstanding": 29605150, "sharesShort": 1262366, "sharesShortPriorMonth": 860796, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.044899996, "heldPercentInsiders": 0.097729996, "heldPercentInstitutions": 0.25063, "shortRatio": 2.76, "shortPercentOfFloat": 0.048, "impliedSharesOutstanding": 29605150, "bookValue": -0.93, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -38060000, "trailingEps": -2.31, "forwardEps": 0.25, "lastSplitFactor": "1:10", "lastSplitDate": 1712016000, "enterpriseToRevenue": 287.865, "enterpriseToEbitda": -4.583, "52WeekChange": 0.6690141, "SandP52WeekChange": 0.14402747, "quoteType": "EQUITY", "currentPrice": 2.37, "targetHighPrice": 47.0, "targetLowPrice": 25.0, "targetMeanPrice": 36.5, "targetMedianPrice": 37.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 7184000, "totalCashPerShare": 0.256, "ebitda": -15199000, "totalDebt": 10256000, "quickRatio": 0.259, "currentRatio": 0.294, "totalRevenue": 242000, "revenuePerShare": 0.014, "returnOnAssets": -0.97826, "grossProfits": 145000, "freeCashflow": 2985500, "operatingCashflow": -12497000, "grossMargins": 0.59916997, "ebitdaMargins": 0.0, "operatingMargins": -17.01653, "financialCurrency": "USD", "symbol": "NRXP", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1766192292, "regularMarketTime": 1766178002, "shortName": "NRX Pharmaceuticals, Inc.", "longName": "NRx Pharmaceuticals, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 8.71559, "regularMarketPrice": 2.37, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1512397800000, "postMarketChangePercent": -0.80167997, "postMarketPrice": 2.351, "postMarketChange": -0.018999815, "regularMarketChange": 0.19, "regularMarketDayRange": "2.2 - 2.41", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 472340, "fiftyTwoWeekLowChange": 0.9699999, "fiftyTwoWeekLowChangePercent": 0.6928571, "fiftyTwoWeekRange": "1.4 - 6.01", "fiftyTwoWeekHighChange": -3.6400003, "fiftyTwoWeekHighChangePercent": -0.6056573, "fiftyTwoWeekChangePercent": 66.90141, "earningsTimestampStart": 1763413200, "earningsTimestampEnd": 1763413200, "earningsCallTimestampStart": 1763386200, "earningsCallTimestampEnd": 1763386200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.31, "epsForward": 0.25, "epsCurrentYear": -1.33, "priceEpsCurrentYear": -1.7819548, "fiftyDayAverageChange": -0.22880006, "fiftyDayAverageChangePercent": -0.08804066, "twoHundredDayAverageChange": -0.2720952, "twoHundredDayAverageChangePercent": -0.10298464, "priceToBook": -2.548387, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "NeuroRx, Inc.", "nameChangeDate": "2025-12-19", "averageAnalystRating": "1.0 - Strong Buy", "cryptoTradeable": false, "exchange": "NCM", "messageBoardId": "finmb_319388181", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "NRx Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-12-20"}]